mutated Ligand Binding Site gene DataBase





About Us

Bioinformatics and Systems Medicine Laboratory Bioinformatics and Systems Medicine Laboratory

Gene Summary

Ligand Binding Site Mutation Information

Protein Structure Related Information

Gene Expression and Gene-Gene Network

Phenotype Information

Pharmacological Information

Conservation Information for LBS

Gene summary for CLK2
Gene summary
Basic gene Info.Gene symbolCLK2
Gene nameCDC-like kinase 2
CytomapUCSC genome browser: 1q21
Type of geneprotein-coding
DescriptionCLK kinasedual specificity protein kinase CLK2
Modification date20141207
dbXrefs MIM : 602989
Ensembl : ENSG00000176444
HPRD : 04289
Vega : OTTHUMG00000035873
ProteinUniProt: P49760
go to UniProt's Cross Reference DB Table
ExpressionCleanEX: HS_CLK2
BioGPS: 1196
PathwayNCI Pathway Interaction Database: CLK2
Pathway Commons: CLK2
ContextiHOP: CLK2
ligand binding site mutation search in PubMed: CLK2
UCL Cancer Institute: CLK2
Assigned class in mutLBSgeneDBB: This gene belongs to targetable_mutLBSgenes.

Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez
GO:0006468protein phosphorylation20682768
GO:0043484regulation of RNA splicing9637771

Ligand binding site mutations for CLK2
Lollipop-style diagram of mutations at LBS in amino-acid sequence.
We represented ligand binding site mutations only. (You can see big image via clicking.)
: non-synonymous mutation on LBS, Circle size denotes number of samples.

Cancer type specific mutLBS sorted by frequency
LBSAAchange of nsSNVCancer type# samples
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma.

Protein structure related information for CLK2
Relative protein structure stability change (ΔΔE) using Mupro 1.1
Mupro score denotes assessment of the effect of mutations on thermodynamic stability.
  (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability)
: nsSNV at non-LBS: nsSNV at LBS

nsSNVs sorted by the relative stability change of protein structure by each mutation
Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene.
LBSAAchange of nsSNVRelative stability change
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132)

Structure image for CLK2 from PDB

Differential gene expression and gene-gene network for CLK2
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types

Differential co-expressed gene network based on protein-protein interaction data (CePIN)
* Left PPI network was created from samples with mutations in the LBS of CLK2 and the right PPI network was created from samples without mutations in the LBS of CLK2. Only genes with p-value < 0.05 are shown.
Red circle: input gene. Orange circle: LBSgene. Blue circle: other gene.


Phenotype information for CLK2
Gene level disease information (DisGeNet)
Disease IDDisease name# PubMedAssociation type

Mutation level pathogenic information (ClinVar annotation)
Allele IDAA changeClinical significanceOriginPhenotype IDs

Pharmacological information for CLK2
Gene expression profile of anticancer drug treated cell-lines (CCLE)
Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient.

Gene-centered drug-gene interaction network
Drug information targeting mutLBSgene (Approved drugs only)
Drug statusDrugBank IDNameTypeDrug structure

Gene-centered ligand-gene interaction network

Ligands binding to mutated ligand binding site of CLK2 go to BioLip
Ligand IDLigand short nameLigand long namePDB IDPDB namemutLBS

Conservation information for LBS of CLK2
Multiple alignments for P49760 in multiple species
LBSAA sequence# speciesSpecies
A191GGARVALKIIK1Homo sapiens
A191KEM-VAVKIVR1Arabidopsis thaliana
A191GGTQVALKIIK1Mus musculus
D327AVRVVDFGSAT2Homo sapiens, Mus musculus
D327AIKVIDFGSTT1Arabidopsis thaliana
E171VSTLGEGTFGR2Homo sapiens, Mus musculus
E171YSKMGEGTFGQ1Arabidopsis thaliana
E208EAARLEINVLE2Homo sapiens, Mus musculus
E208EAAMIEIEMLQ1Arabidopsis thaliana
E244MCISFELLGLS2Homo sapiens, Mus musculus
E244ICIVFEKLGSS1Arabidopsis thaliana
F174LGEGTFGRVVQ2Homo sapiens, Mus musculus
F174MGEGTFGQVLE1Arabidopsis thaliana
F243HMCISFELLGL2Homo sapiens, Mus musculus
F243HICIVFEKLGS1Arabidopsis thaliana
G172STLGEGTFGRV2Homo sapiens, Mus musculus
G172SKMGEGTFGQV1Arabidopsis thaliana
K193ARVALKIIKNV1Homo sapiens
K193M-VAVKIVRGV1Arabidopsis thaliana
K193TQVALKIIKNV1Mus musculus
L169EIVSTLGEGTF2Homo sapiens, Mus musculus
L169KIYSKMGEGTF1Arabidopsis thaliana
L245CISFELLGLST2Homo sapiens, Mus musculus
L245CIVFEKLGSSL1Arabidopsis thaliana
L246ISFELLGLSTF2Homo sapiens, Mus musculus
L246IVFEKLGSSLY1Arabidopsis thaliana
L297KPENILFVNSD2Homo sapiens, Mus musculus
L297KPENILLVSSD1Arabidopsis thaliana
N295DLKPENILFVN2Homo sapiens, Mus musculus
N295DLKPENILLVS1Arabidopsis thaliana
V177GTFGRVVQCVD2Homo sapiens, Mus musculus
V177GTFGQVLECWD1Arabidopsis thaliana
V326TAVRVVDFGSA2Homo sapiens, Mus musculus
V326SAIKVIDFGST1Arabidopsis thaliana

Copyright © 2016-Present - The University of Texas Health Science Center at Houston
Site Policies | State of Texas